• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肾脏病患者中出现心力衰竭特征但尚未被诊断为心力衰竭的症状。

Symptoms characteristic of heart failure among CKD patients without diagnosed heart failure.

机构信息

University of California, San Francisco, General Internal Medicine, San Francisco VA Medical Center, 4150 Clement St., 111A1, San Francisco, CA 94109, USA.

出版信息

J Card Fail. 2011 Jan;17(1):17-23. doi: 10.1016/j.cardfail.2010.08.009.

DOI:10.1016/j.cardfail.2010.08.009
PMID:21187260
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3011973/
Abstract

BACKGROUND

Epidemiological studies typically diagnose heart failure (HF) at the time of hospitalization, and have not evaluated the prevalence of HF symptoms in CKD patients without a prior HF diagnosis.

METHODS AND RESULTS

We modified the Kansas City Cardiomyopathy Questionnaire (KCCQ) to detect and quantify symptoms characteristic of HF (dyspnea, edema, and fatigue) among 2883 chronic kidney disease (CKD) patients without diagnosed heart failure in the Chronic Renal Insufficiency Cohort (CRIC). The KCCQ is a 23-item instrument that quantifies the impact of dyspnea, fatigue, and edema on physical, social, and emotional functions (scored 0 to 100). The median KCCQ score was 92, and 25% had KCCQ scores <75. Compared with cystatin C‑based estimated glomerular filtration rate >50 mL·min·1.73 m(2) (reference), estimated glomerular filtration rate 40 to 50, 30 to 40, and <30 were independently associated with lower KCCQ scores (<75); adjusted odds ratios and (95% CI): 1.38 (1.06-1.78), 1.39 (1.09-1.82), and 2.15 (1.54-3.00), respectively. Lower hemoglobin (Hb) levels also had independent associations with KCCQ <75: Hb >14 g/dL (reference), Hb 13 to 14 g/dL (1.03; 0.76-1.40), Hb 12 to 13 g/dL (1.41; 1.04-1.91), Hb 11 to 12 g/dL (1.56; 1.12-2.16); and Hb <1 g/dL (1.65; 1.15-2.37).

CONCLUSION

CKD patients without diagnosed HF have a substantial burden of symptoms characteristic of HF, particularly among those with lower estimated glomerular filtration rate and hemoglobin levels.

摘要

背景

流行病学研究通常在住院时诊断心力衰竭(HF),并未评估先前未诊断 HF 的 CKD 患者的 HF 症状的患病率。

方法和结果

我们修改了堪萨斯城心肌病问卷(KCCQ),以检测和量化 2883 例慢性肾脏病(CKD)患者中无诊断心力衰竭的慢性肾功能不全队列(CRIC)中 HF 特征性症状(呼吸困难,水肿和疲劳)。KCCQ 是一种 23 项工具,可量化呼吸困难,疲劳和水肿对身体,社会和情感功能的影响(评分 0 至 100)。KCCQ 的中位数评分为 92,25%的 KCCQ 评分<75。与胱抑素 C 估计肾小球滤过率>50 mL·min·1.73 m2(参考)相比,估计肾小球滤过率为 40 至 50、30 至 40 和<30 与较低的 KCCQ 评分(<75)独立相关;调整后的优势比和(95%CI):1.38(1.06-1.78),1.39(1.09-1.82)和 2.15(1.54-3.00)。较低的血红蛋白(Hb)水平也与 KCCQ<75 独立相关:Hb>14 g/dL(参考),Hb 13 至 14 g/dL(1.03;0.76-1.40),Hb 12 至 13 g/dL(1.41;1.04-1.91),Hb 11 至 12 g/dL(1.56;1.12-2.16);和 Hb<1 g/dL(1.65;1.15-2.37)。

结论

先前未诊断 HF 的 CKD 患者 HF 特征性症状负担很大,尤其是在估计肾小球滤过率和血红蛋白水平较低的患者中。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67dd/3011973/05ecab3b1149/nihms232767f3a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67dd/3011973/ea73d4b16625/nihms232767f1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67dd/3011973/78170cbfe6b2/nihms232767f2a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67dd/3011973/05ecab3b1149/nihms232767f3a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67dd/3011973/ea73d4b16625/nihms232767f1a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67dd/3011973/78170cbfe6b2/nihms232767f2a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67dd/3011973/05ecab3b1149/nihms232767f3a.jpg

相似文献

1
Symptoms characteristic of heart failure among CKD patients without diagnosed heart failure.慢性肾脏病患者中出现心力衰竭特征但尚未被诊断为心力衰竭的症状。
J Card Fail. 2011 Jan;17(1):17-23. doi: 10.1016/j.cardfail.2010.08.009.
2
Heart Failure-Type Symptom Score Trajectories in CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.慢性肾脏病中的心力衰竭样症状评分轨迹:慢性肾功能不全队列(CRIC)研究的结果。
Am J Kidney Dis. 2023 Apr;81(4):446-456. doi: 10.1053/j.ajkd.2022.09.016. Epub 2022 Nov 18.
3
Association of Cardiac Biomarkers With the Kansas City Cardiomyopathy Questionnaire in Patients With Chronic Kidney Disease Without Heart Failure.慢性肾脏病且无心力衰竭患者中心脏生物标志物与堪萨斯城心肌病问卷的相关性。
J Am Heart Assoc. 2020 Jul 7;9(13):e014385. doi: 10.1161/JAHA.119.014385. Epub 2020 Jun 24.
4
Kansas City Cardiomyopathy Questionnaire Score Is Associated With Incident Heart Failure Hospitalization in Patients With Chronic Kidney Disease Without Previously Diagnosed Heart Failure: Chronic Renal Insufficiency Cohort Study.堪萨斯城心肌病问卷评分与既往未诊断为心力衰竭的慢性肾脏病患者发生心力衰竭住院相关:慢性肾功能不全队列研究。
Circ Heart Fail. 2015 Jul;8(4):702-8. doi: 10.1161/CIRCHEARTFAILURE.115.002097. Epub 2015 May 18.
5
Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.慢性肾脏病与替尔泊肽对射血分数保留的肥胖心力衰竭患者的影响:SUMMIT试验
J Am Coll Cardiol. 2025 May 13;85(18):1721-1735. doi: 10.1016/j.jacc.2025.03.009. Epub 2025 Mar 31.
6
Association of Serial Kansas City Cardiomyopathy Questionnaire Assessments With Death and Hospitalization in Patients With Heart Failure With Preserved and Reduced Ejection Fraction: A Secondary Analysis of 2 Randomized Clinical Trials.连续堪萨斯城心肌病问卷评估与射血分数保留和降低的心衰患者死亡和住院的相关性:两项随机临床试验的二次分析。
JAMA Cardiol. 2017 Dec 1;2(12):1315-1321. doi: 10.1001/jamacardio.2017.3983.
7
Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction.合并症对心力衰竭伴射血分数降低和保留患者健康状况(采用堪萨斯城心肌病问卷进行测量)的影响。
Eur J Heart Fail. 2023 Sep;25(9):1606-1618. doi: 10.1002/ejhf.2962. Epub 2023 Aug 3.
8
Heart failure-type symptom scores in chronic kidney disease: The importance of body mass index.慢性肾脏病患者心力衰竭样症状评分:体重指数的重要性。
Int J Obes (Lond). 2022 Oct;46(10):1910-1917. doi: 10.1038/s41366-022-01208-x. Epub 2022 Aug 17.
9
Validation of heart failure quality of life tool and usage to predict all-cause mortality in acute heart failure in Uganda: the Mbarara heart failure registry (MAHFER).乌干达急性心力衰竭中心衰生活质量工具的验证及其用于预测全因死亡率:姆巴拉拉心力衰竭登记研究(MAHFER)。
BMC Cardiovasc Disord. 2018 Dec 12;18(1):232. doi: 10.1186/s12872-018-0959-1.
10
Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry.心力衰竭门诊患者不同医疗实践中的健康状况差异:来自CHAMP-HF(改变心力衰竭患者管理)注册研究的见解
Circ Cardiovasc Qual Outcomes. 2018 Apr;11(4):e004668. doi: 10.1161/CIRCOUTCOMES.118.004668.

引用本文的文献

1
Heart failure events in randomized controlled trials for adults receiving maintenance dialysis: a meta-epidemiologic study.接受维持性透析的成人患者随机对照试验中的心力衰竭事件:一项元流行病学研究。
Nephrol Dial Transplant. 2025 Feb 4;40(2):371-384. doi: 10.1093/ndt/gfae156.
2
Heart Failure-Type Symptom Score Trajectories in CKD: Findings From the Chronic Renal Insufficiency Cohort (CRIC) Study.慢性肾脏病中的心力衰竭样症状评分轨迹:慢性肾功能不全队列(CRIC)研究的结果。
Am J Kidney Dis. 2023 Apr;81(4):446-456. doi: 10.1053/j.ajkd.2022.09.016. Epub 2022 Nov 18.
3
Heart failure-type symptom scores in chronic kidney disease: The importance of body mass index.慢性肾脏病患者心力衰竭样症状评分:体重指数的重要性。
Int J Obes (Lond). 2022 Oct;46(10):1910-1917. doi: 10.1038/s41366-022-01208-x. Epub 2022 Aug 17.
4
Speckle-tracking echocardiography in comparison with ejection fraction for prediction of cardiovascular mortality in patients with end-stage renal disease.斑点追踪超声心动图与射血分数在预测终末期肾病患者心血管死亡率方面的比较
Clin Kidney J. 2021 Jan 19;14(6):1579-1585. doi: 10.1093/ckj/sfaa161. eCollection 2021 Jun.
5
Baseline characteristics of patients in the PARALLAX trial: insights into quality of life and exercise capacity in heart failure with preserved ejection fraction.PARALLAX 试验患者的基线特征:射血分数保留的心力衰竭患者生活质量和运动能力的深入了解。
Eur J Heart Fail. 2021 Sep;23(9):1541-1551. doi: 10.1002/ejhf.2277. Epub 2021 Jul 26.
6
Association of Cardiac Biomarkers With the Kansas City Cardiomyopathy Questionnaire in Patients With Chronic Kidney Disease Without Heart Failure.慢性肾脏病且无心力衰竭患者中心脏生物标志物与堪萨斯城心肌病问卷的相关性。
J Am Heart Assoc. 2020 Jul 7;9(13):e014385. doi: 10.1161/JAHA.119.014385. Epub 2020 Jun 24.
7
Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach.从临床前到射血分数保留的临床心力衰竭的转变:一种机制性方法。
J Clin Med. 2020 Apr 13;9(4):1110. doi: 10.3390/jcm9041110.
8
Diagnosis and Management of Pulmonary Hypertension in Patients With CKD.慢性肾脏病患者肺动脉高压的诊断与治疗。
Am J Kidney Dis. 2020 Jun;75(6):935-945. doi: 10.1053/j.ajkd.2019.12.005. Epub 2020 Mar 19.
9
Renal function monitoring in heart failure - what is the optimal frequency? A narrative review.心力衰竭患者的肾功能监测——最佳频率是多少?一篇综述。
Br J Clin Pharmacol. 2018 Jan;84(1):5-17. doi: 10.1111/bcp.13434. Epub 2017 Oct 22.
10
Prevalence and Prognostic Significance of Apparent Treatment Resistant Hypertension in Chronic Kidney Disease: Report From the Chronic Renal Insufficiency Cohort Study.慢性肾脏病中貌似治疗抵抗性高血压的患病率及预后意义:慢性肾功能不全队列研究报告
Hypertension. 2016 Feb;67(2):387-96. doi: 10.1161/HYPERTENSIONAHA.115.06487. Epub 2015 Dec 28.

本文引用的文献

1
Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function.慢性肾功能不全队列(CRIC)研究:基线特征及其与肾功能的关联
Clin J Am Soc Nephrol. 2009 Aug;4(8):1302-11. doi: 10.2215/CJN.00070109. Epub 2009 Jun 18.
2
Patient health status and costs in heart failure: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study (EPHESUS).心力衰竭患者的健康状况与成本:依普利酮急性心肌梗死后心力衰竭疗效和生存研究(EPHESUS)的见解
Circulation. 2009 Jan 27;119(3):398-407. doi: 10.1161/CIRCULATIONAHA.108.820472. Epub 2009 Jan 12.
3
Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD.单独使用血清胱抑素C以及联合血清肌酐估算肾小球滤过率:对3418例慢性肾脏病患者的汇总分析
Am J Kidney Dis. 2008 Mar;51(3):395-406. doi: 10.1053/j.ajkd.2007.11.018.
4
Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study.肾功能减退作为新发心力衰竭的危险因素:社区动脉粥样硬化风险(ARIC)研究
J Am Soc Nephrol. 2007 Apr;18(4):1307-15. doi: 10.1681/ASN.2006101159. Epub 2007 Mar 7.
5
Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease.胱抑素C与无慢性肾脏病老年人的心血管及肾脏预后
Ann Intern Med. 2006 Aug 15;145(4):237-46. doi: 10.7326/0003-4819-145-4-200608150-00003.
6
Renal function and heart failure risk in older black and white individuals: the Health, Aging, and Body Composition Study.老年黑人和白人的肾功能与心力衰竭风险:健康、衰老和身体成分研究
Arch Intern Med. 2006 Jul 10;166(13):1396-402. doi: 10.1001/archinte.166.13.1396.
7
Health status identifies heart failure outpatients at risk for hospitalization or death.健康状况可识别出有住院或死亡风险的心力衰竭门诊患者。
J Am Coll Cardiol. 2006 Feb 21;47(4):752-6. doi: 10.1016/j.jacc.2005.11.021. Epub 2006 Jan 26.
8
Cystatin C concentration as a risk factor for heart failure in older adults.胱抑素C浓度作为老年人心力衰竭的一个风险因素。
Ann Intern Med. 2005 Apr 5;142(7):497-505. doi: 10.7326/0003-4819-142-7-200504050-00008.
9
The clinical challenge of cardiorenal syndrome.心肾综合征的临床挑战。
Circulation. 2004 Sep 21;110(12):1514-7. doi: 10.1161/01.CIR.0000143547.55093.17.
10
Predictors of heart failure among women with coronary disease.冠心病女性心力衰竭的预测因素。
Circulation. 2004 Sep 14;110(11):1424-30. doi: 10.1161/01.CIR.0000141726.01302.83. Epub 2004 Sep 7.